

Curriculum Vitae

Carson David Liu, M.D., F.A.C.S.

Business Address: SkyLex Advanced Surgical, Inc.
1301 20th Street, Suite 440
Santa Monica, CA 90404

Phone: 310-208-0474 (office)
310-208-0374 (FAX)

Email: Doc@DrCarsonLiu.com

Date of Birth: February 18, 1965 - Chicago, Illinois

Employment

OBand Centers, Los Angeles and Orange County Medical Director	2006-2011
Clinical Assistant Professor of Surgery, UCLA School of Medicine	2003-Present
Midway/Olympia Hospital, Minimally Invasive Bariatric Surgery, Medical Director	2004-2008
Garden Grove Hospital, Medical Director of Bariatric Surgery	2006-2007
Century City Hospital, Minimally Invasive Bariatric Surgery, Medical Director	2003-2004
UCLA Medical School, Department of Surgery, Assistant Professor in Residence	1998-2003
West Los Angeles Veterans Hospital, Staff Surgeon	1998-2004
Director of Surgical Intensive Care Unit	2001-2004
UCLA/Santa Monica Hospital, Attending Staff Surgeon	1998-Present

Education

- UCLA Medical Center, Department of Surgery
 Division of General Surgery
 Chief Resident 1997-1998
 Senior Resident 1996-1997
 Assistant Resident 1995-1996
 Research Fellow 1993-1995
 Resident 1992-1993
 Intern 1991-1992

- UNIVERSITY OF CHICAGO, Pritzker School of Medicine
 M.D. 1991

- UNIVERSITY OF CHICAGO
 Major: Chemistry
 A.B. 1987

Licensure:

National Board of Medical Examiners	404078
California State Medical Board	G075372
Drug Enforcement Agency	BL3425508

Board Certified in General Surgery #44260
Re-certified in 2008

Expires 2019

Awards

- American Diabetes Association Father of the Year Award 2004
- Wilma Miley Morton Research Award, UCLA Resident Research Award 1998
- Administrative Chief Resident 1997-1998
- Society for Surgery of the Alimentary Tract/Ross Laboratories Participant 1995
- Society for Surgery of the Alimentary Tract/Ross Laboratories Participant 1994
- General and Special Honors from the Dept. of Chemistry, U. of Chicago 1987
- NIH Biomedical Research Conference Participant-Bethesda, MD 1987
- Dean's List at University of Chicago 1983-1986
- Salutatorian, Hoffman Estates High School 1983
- Hoffman Estates Loyal Parents Merit Scholarship 1983
- Illinois State Scholar 1983
- National Honor Society 1981-1983

Committees

- Surgery Committee, Olympia Medical Center 2005-Present
- VA SICU/HICU Critical Care Committee 2000-2004
- Minimally Invasive Surgery Institute UCLA-Executive Committee 2000-2003
- Residency Review Committee Member, UCLA School of Medicine 1997-2003
- UCLA Executive Medical Center Liaison Committee 1997-1999

Professional Associations

- Editorial Board, Journal of Surgical Research 2000-2003
- Fellow of American College of Surgeons 2001-Present
- Los Angeles Surgical Society 2001-2005
- American Society for Bariatric Surgery 2000-Present
- Association for Academic Surgery 1999-2005
- Society for Surgery of the Alimentary Tract 1999-Present
- American College of Surgeons, Associate 1999-2001
- Council Advisory Board Member, Allergan 2007-Present

Research Experience

- UCLA School of Medicine, Assistant Professor in Residence 1998-2003
- UCLA Medical Center, Department of Surgery, Dr. David McFadden 1993-5
Gastrointestinal Hormones: Intestinal Absorption and Pancreatic Cancer
- Argonne National Laboratories, Biological and Medical 1986-7
Research Division, Dr. Edwin Westbrook
Protein Structure of Human Neutrophilic Cationic Protein
- University of Chicago, Department of Chemistry, Dr. Leon Stock 1985
BA Thesis: Deuterium Substitution into Aromatic Rings of Coal
Paper accepted for Honors by the Department of Chemistry

Research Support

- Green Zone Study, Allergan, Principal Investigator 2010
- HERO Study, Allergan, Principal Investigator 2010
- GOAL Study, EasyBand Remote Control Band, FDA Trial. 2007
Principal Investigator
- APEX Lap Band Study-Allergan, Principal Investigator 2007-Present
- Impact Clinical Trials-A double blind, placebo controlled pharmacodynamic study of the effect of INCB013739 on systemic and adipose tissue 11 β HSD1 activity in obese, insulin resistant subjects.
Protocol Number INCB 13739-103, Subinvestigator 2006-2007
- National Institute of Health Clinical Nutrition Research Unit Grant – Lycopene and Pancreatic Cancer, Award # CA42710, NIH CNRU PF# 441483LD
\$22,800, Principal Investigator 2001-2002
- Merck & Co., Inc. - Cyclooxygenase-2 Inhibitors for the Treatment of Pancreatic Cancer, Educational Grant
\$1,500 + \$10,000 in Product, Principal Investigator 2001-2002
- Robotic Minimally Invasive Surgery for Diabetes and Obesity 2000-2003
UCLA Department of Surgery/Gonda(Goldschmeid) Fund
\$3,000,000 Donation for Minimally Invasive Robots from the Gonda Family to UCLA
- Baxter Biosciences- Tisseel, Fibrin Sealant, for High Risk Bowel Anastomosis: Laparoscopic Gastric Bypass Roux en Y in the Porcine Model.
\$40,000, Principal Investigator 2001-2002
- Ethicon Endosurgery-“Laparoscopic Gastric Bypass in the Porcine Model, Evaluation of the Linear Stapled Gastrojejunostomy”
\$10,000, Principal Investigator 2000-2002

- American Cancer Society-“Hypericin Phototherapy and Pancreatic Cancer”
\$75,000, Co-Principal Investigator 2000-2001
- State of California, Department of Health Services – “Synthetic Gut Hormones
in the Treatment of Pancreatic Cancer”-\$294,710
Principal Investigator, Project #99-00537V-10220 1999-2001
- “Laparoscopic vs. Open Gastric Bypass Roux en Y” in Humans
IRB#98-09-026-02, University of California Los Angeles,
Principal Investigator 1998-2003
- VA Cooperative Study-“Laparoscopic vs. Open Hernia Repair with Mesh”
Co-Principal Investigator 1998-2002
- Leon Hirsch Research Scholarship, American Society of Colorectal
Surgeons Research Foundation - \$30,000 Principal Investigator 1994
- NIH Student Summer Research Award - \$2,500 1988
- Richter Fellowship Research Fund Recipient - \$2,500 1987

Publications

1. **Liu CD**, Stock L. Deuterium substitution into coal with ²H trifluoroacetic acid. BA Thesis. Department of Chemistry, University of Chicago. 1987. Accepted for Special Honors Paper.
2. **Liu CD**, Whang EE, Hines OJ, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal peptide YY is proabsorptive in the canine ileum in vivo. *Surgical Forum*, **25**:176-178, 1994.
3. Whang EE, Hines OJ, **Liu CD**, Reeve JR, Bilchik AJ, Moser AJ, Zinner MJ, McFadden DW, Ashley SW. Mechanisms of peptide YY - induced colonic absorption. *Surgical Forum*, **25**:204-206, 1994.
4. Bilchik AJ, Hines OJ, Ashley SW, Adrian TE, **Liu CD**, Wong H, Zinner MJ, McFadden DW. Peptide YY immunoneutralization inhibits meal-induced absorption in vivo. *Surgery*, **116**(6): 1153-1158, 1994.
5. **Liu CD**, Hines OJ, Whang EE, Laird EC, Skotzko MJ, Zinner MJ, Ashley SW, McFadden DW. Pancreatic peptide YY mRNA levels increase during adaptation after small intestinal resection. *Journal of Surgical Research*, **58**(1):6-11, 1995.
6. Hines OJ, Bilchik AJ, Ashley SW, Whang EE, **Liu CD**, Zinner MJ, McFadden DW. Amino acids mediate postprandial jejunal proabsorption. *Journal of Surgical Research*, **58**(1):81-85, 1995.

7. **Liu CD**, Balasubramaniam A, Saxton RE, Paiva M, McFadden DW. Human pancreatic cancer growth is inhibited by peptide YY and its synthetic analog, BIM-43004-1. *Journal of Surgical Research*, **58**:707-712, 1995.
8. **Liu CD**, Hines OJ, Whang EE, Balasubramaniam A, Newton TR, Zinner MJ, Ashley SW, McFadden DW. A novel synthetic analog of peptide YY given intraluminally induces intestinal absorption. *Journal of Surgical Research*, **59**:80-84, 1995.
9. **Liu CD**, Rolandelli R, Ashley SW, Evans B, Shin M, McFadden DW. Laparoscopic intestinal surgery in inflammatory bowel disease patients. *American Surgeon*, **61**:1054-1056, 1995.
10. **Liu CD**, Slice L, Balasubramaniam A, Walsh JH, Newton TR, Saxton RE, McFadden DW. Y2 receptors decrease human pancreatic cancer growth and intracellular cAMP levels. *Surgery*, **118**: 229-236, 1995.
11. Rongione AJ, **Liu CD**, Whang EE, Dunn J, Newton TA, Zinner MJ, Ashley SW, McFadden DW: Epidermal growth factor enhances small intestinal absorption. *Surgical Forum*, **46**: 188-191, 1995.
12. **Liu CD**, Hines OJ, Newton TR, Adrian TE, Zinner MJ, Ashley SW, McFadden DW. Cholecystokinin mediates colonic absorption: A foregut-hindgut axis. *World Journal of Surgery*, **20**:221-227, 1996.
13. **Liu CD**, Aloia T, Hines OJ, Bilchik AJ, Whang EE, MD, Newton TR, Zinner MJ, Ashley SW, and McFadden DW. Peptide YY: A potential proabsorptive enteric hormone in the treatment of colonic malabsorptive disorders. *American Surgeon*, **62**:232-236, 1996.
14. Whang EE, Dunn JC, **Liu CD**, Newton T, Zinner MJ, McFadden DW, Ashley SW. Amiloride inhibits meal-induced colonic absorption. *Journal of Surgical Research*, **60**:303-306, 1996.
15. **Liu CD**, Rongione AJ, Garvey L, Balasubramaniam A, McFadden DW. Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth and EGF receptor expression. *American Journal of Surgery*, **171**:192-196, 1996.
16. Balasubramaniam A, Stein M, Fischer JE, Taylor JE, Eden P, Voisin T, Laburthe M, **Liu CD**, McFadden DW. Synthesis and Binding Properties of PYY(22-36) Analogs: Development of a potent proabsorptive peptide. *Proc Am Pep Symp*, 1996.
17. **Liu CD**, Rongione AJ, Shin M, Ashley SW, McFadden DW. Epidermal growth factor improves intestinal adaptation during somatostatin administration. *Journal of Surgical Research*, **63**:163-168, 1996.
18. **Liu CD**, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal PYY induces colonic absorption in vivo. *Dis Colon and Rectum*, **40**:478-482, 1997.

19. **Liu CD**, McFadden DW. Overnight closed suction drainage after lumpectomy and axillary lymphadenectomy for breast cancer. *American Surgeon*, **63**(10):868-870, 1997.
20. Heisler T, Towfigh S, Simon N, **Liu C**, McFadden DW. Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth. *Journal of Surgical Research*, **88**(1):23-5, 2000.
21. Balasubramaniam A, Tao Z, Zhai W, Stein M, Sheriff S, Chance WT, Fischer JE, Eden PE, Taylor JE, **Liu CD**, McFadden DW, Voisin T, Roze C, Laburthe M. Structure-activity studies including A Ψ (CH₂-NH) scan of Peptide YY. (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogs with potent in vivo activity in the intestine. *J. Medicinal Chemistry*, **43**(18):3420-7, 2000.
22. **Liu CD**, Kwan D, Saxton RE, McFadden DW. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. *Journal of Surgical Research*, **93**(1):137-143, 2000.
23. Paiva MB, Saxton RE, Blackwell KE, Buechler P, Cohen A, **Liu CD**, Calcaterra TC, Ward PH, Castro DJ. Combined cisplatinum and laser thermal therapy for palliation of recurrent head and neck tumors. *Diagnostic and Therapeutic Endoscopy*, **6**:133-140, 2000.
24. **Liu CD**, McFadden DW. Laparoscopic port sites do not require fascial closure when using non-bladed trocars. *American Surgeon* **66**(9):853-4, 2000.
25. **Liu CD**, Kwan D, Simon N, McFadden DW. Synthetic Peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells. *Journal of Gastrointestinal Surgery* **5**:147-152, 2001.
26. **Liu CD**, Deganutti A, Saxton RE. Cyclooxygenase-2 (COX-2) inhibition decreases human pancreatic cancer cell growth and angiogenesis. *Surgical Forum*, **52**:211-212, 2001.
27. Chen M, Kwan D, Saxton RE, **Liu CD**. Hypericin photodynamic therapy decreases melanoma cell growth in vitro. *Surgical Forum*, **52**:233-235, 2001.
28. Huerta S, Heber D, Sawicki MP, **Liu CD**, Arthur D, Alexander P, Yip I, Li ZP, Livingston EH. Reduced length of stay by implementation of a clinical pathway for bariatric surgery in an academic health care center. *American Surgeon*, **67**:1128-35, 2001.
29. **Liu CD**, Higa K, Guenther M, et al. Fibrin Sealants in Surgery. *Surgical Rounds*, 2001.
30. Huerta S, DeShields S, Shpiner R, Li Z, **Liu C**, Sawicki M, Heber D, Livingston EH. Safety and efficacy of postoperative continuous positive airway pressure (CPAP) to prevent pulmonary complications for patients following upper gastrointestinal anastomosis. *Journal of Gastrointestinal Surgery*, **6**:354-8, 2002.
31. Huerta S, Rogers LM, Li Z, Heber D, **Liu C**, Livingston E. Vitamin A deficiency in a newborn due to maternal vitamin A deficiency after biliopancreatic diversion for the

- treatment of morbid obesity: a case report. *American Journal of Clinical Nutrition*, **76**:426-9, 2002.
32. **Liu CD**, Tilch L, Kwan D, McFadden DW. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. *Journal of Surgical Research*, **102**:31-34, 2002.
 33. Tseng WW, **Liu CD**. Peptide YY and Cancer: Current Findings and Potential Clinical Applications. *Peptides*, **23**:389-395, 2002.
 34. Paiva MB, Blackwell KE, Saxton RE, Bublik M, **Liu CD**, Paiva Paolini AA, Calcaterra TC, Castro DJ. Nd:YAG laser therapy for palliation of recurrent squamous cell carcinomas in the oral cavity. *Lasers Surg Med*, **31**:64-9, 2002.
 35. Huerta S, Arteaga JR, Sawicki MP, **Liu CD**, Livingston EH. Assessment of routine elimination of postoperative nasogastric decompression following Roux-en-Y gastric bypass. *Surgery*, **132**(5):844-8, 2002.
 36. Tseng WW, Deganuti A, Chen MN, Saxton RE, **Liu CD**. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. *J Gastrointestinal Surgery*, **6**:838-43, 2002.
 37. Tseng WW, Saxton RE, Kwan DK, **Liu CD**. Indocyanine green decreases cell viability and impairs production of vascular endothelial growth factor in pancreatic cancer. In Press. *Pancreas*, 2003.
 38. **Liu CD**, Glantz GJ, Livingston EH. Fibrin glue as a sealant for high-risk anastomosis for morbid obesity surgery. *Obesity Surgery*, **13**(1):45-8, 2003.
 39. Tseng WT, Saxton RE, Deganutti A, Liu CD. Infrared laser activation of indocyanine green inhibits growth in human pancreatic cancer. *Pancreas*, **27**(2):1-4, 2003.
 40. DonMichael TA, Sultana Y, **Liu CD**, Dettmers-Smith S, Gray L. Short Term Changes in the Metabolic Syndrome with Regression of Type II Diabetes following Bariatric Surgery. Submitted to *The Bariatrician*, 2007.

Book Chapters

1. **Liu CD**, McFadden DW. Acute abdomen and appendix. *Surgery: Scientific Principles and Practice*. Second Edition. J.B. Lippincott Company. Greenfield, Mulholland, Zelenock, Oldham (Eds). 1997.
2. **Liu CD**, McFadden DW. Pre- and post-operative care. *Maingot's Abdominal Operations*. 10th Edition. Zinner MJ, Schwartz SI, Ellis H (Eds). 1997.
3. **Liu CD**, Whang EE, Corman M. Crohn's disease. *Prognosis and Outcome Expectancy of Surgical Diseases*. Reiling, Eiseman, McKellar (Eds). 2000.

Reviews

1. **Liu CD.** Review of The Esophagogastric Junction: 420 Questions, 420 Answers, Vol 5. R Giuli, JP Galmeche, GG Jamieson, C Scarpignato (Eds.) *World Journal of Surgery*, **23**(9):985, 1999.
2. **Liu CD.** Review of Principles and Practice of Surgery for the Colon, Rectum and Anus. PH Gordon and S Nivatvongs (Eds.) *World Journal of Surgery*, **23**(12): 1320-1, 1999.
3. **Liu CD.** Review of Laparoscopic Cholecystectomy (CD-ROM)-Version 2.0. G Bonatsos, K Birbas, M Glyntasis (Eds.). *World Journal of Surgery*, **23**(12): 1323, 1999.
4. **Liu CD.** Minimal Access Surgical Anatomy. CEH Scott-Conner, A Cuschieri, FJ Carter (Eds.). *World Journal of Surgery*, 2001.
5. **Liu CD.** Review of Surgical Laparoscopy. Zucker (Ed). *World Journal of Surgery*, 2001
6. **Liu CD.** Review of Minimally Invasive Abdominal Surgery. Kremer, Platzer, Wilhelm Schreiber, Steichen (Eds.) *World Journal of Surgery*, 2001.

Abstracts

1. **Liu CD**, Aloia T, Hines OJ, Ashley SW, Bilchik AJ, Whang EE, Zinner MJ, Newton TR, McFadden DW. Peptide YY is a proabsorptive agent in the canine colon in vivo. *Gastroenterology* **106**:A248, 1994.
2. Hines OJ, Whang EE, **Liu CD**, Skotzko MJ, Newton T, Zinner MJ, Ashley SW, McFadden DW. Peptide YY and the brush border intestinal Na/glucose cotransporter. *Gastroenterology* **106**:A238, 1994.
3. Whang EE, Hines OJ, **Liu CD**, Reeves J, Moser J, Bilchik A, Zinner MJ, McFadden DW, Ashley, D.W.: Both Y-1 specific and Y-2 specific Peptide YY agonists modulate colonic ion transport. *Gastroenterology*, **106**:A279, 1994.
4. Hines OJ, Whang EE, **Liu CD**, Bilchik AJ, Joffe H, Wong H, Zinner MJ, Ashley SW, McFadden DW. Effects of peptide YY and oxyntomodulin immunoneutralization following intestinal resection. *Gastroenterology* **106**:A815, 1994.
5. **Liu CD**, Hines OJ, Whang EE, Skotzko MJ, Laird EC, Zinner MJ, Ashley SW, McFadden DW. Cholecystokinin receptor blockade increases peptide YY mRNA following intestinal resection. *Gastroenterology* **106**:A822, 1994.
6. **Liu CD**, Hines OJ, Whang EE, Bilchik AJ, Ashley SW, Zinner MJ, Newton TR, McFadden DW. Cholecystokinin (CCK) mediates colonic absorption via peptide YY (PYY). *American Journal of Surgery*, **167**(4):451, 1994.

7. **Liu CD**, Balasubramaniam A, Hines OJ, Whang EE, Newton TR, Zinner MJ, Ashley SW, McFadden DW. A new synthetic analogue of peptide YY, BIM-4004-1, is proabsorptive in the small intestine of awake dogs. *Digestive Diseases and Sciences*, **39**(8): 1826, 1994.
8. **Liu CD**, Aloia T, Hines OJ, Adrian TE, Whang EE, Zinner MJ, Ashley SW, McFadden DW. Cholecystokinin receptor blockade down regulates Na⁺/K⁺ cotransporter mRNA after intestinal resection. *Digestive Diseases and Sciences*, **39**(8): 1816, 1994.
9. **Liu CD**, Hines OJ, Whang EE, Bilchik A, Ashley SW, Zinner MJ, McFadden DW. Cholecystokinin mediates colonic absorption via peptide YY. *American Journal of Surgery*, **167**:450, 1994.
10. Whang EE, Hines OJ, **Liu CD**, Reeve JR, Moser AJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. The role of peptide YY receptor subtypes in colonic ion transport regulation. *Digestive Diseases and Sciences*, **39**(8): 1803, 1994.
11. **Liu CD**, Hines OJ, Whang EE, Newton TR, Adrian TE, Zinner MJ, Ashley SW, McFadden DW. Cholecystokinin mediates colonic absorption. *World Journal of Surgery*, **S40**, 1994.
12. **Liu CD**, Rongione A, Garvey L, Balasubramaniam A, McFadden DW. Adjuvant hormonal treatment with peptide YY or its analogue decreases human pancreatic carcinoma growth and EGF-receptor expression. *American Journal of Surgery*, **169**:457, 1995.
13. Rongione AJ, **Liu CD**, Kwan KY, Ashley SW, McFadden DW. Gene therapy in intestinal epithelium. *Gastroenterology*, **108**(4):A318, 1995.
14. **Liu CD**, Rongione AJ, Shin M, Kwan KY, Ashley SW, McFadden DW. Intestinal adaptation is regulated by systemic factors independent of intraluminal contents. *Gastroenterology*, **108**(4):A736, 1995.
15. Rongione AJ, **Liu CD**, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Inhibitory effects of galanin on colonic absorption. *Gastroenterology*, **108**(4):A318, 1995.
16. Rongione AJ, **Liu CD**, Bilchik AJ, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal bile salts regulate small bowel absorption. *Gastroenterology*, **108**(4):A751, 1995.
17. **Liu CD**, Rongione AJ, Garvey L, Balasubramaniam A, McFadden DW. Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth and EGF receptor expression. *Gastroenterology*, **108**(4):A1229, 1995.
18. **Liu CD**, Rongione AJ, Shin M, Kwan K, Ashley SW, McFadden DW. Intestinal adaptation is regulated by systemic factors independent of intraluminal contents. *Gastroenterology*, **108**: A736, 1995.

19. Rongione AJ, **Liu CD**, Evans BS, Newton TR, Kwan KY, Balasubramaniam A, McFadden DW. Hormonal treatment with peptide YY or its analogs decreases human breast carcinoma growth. *The Physiologist*, **38**:A258, 1995.
20. Rongione AJ, **Liu CD**, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Short chain fatty acids mediate intestinal absorption. *Gastroenterology*, **110**:A1414, 1996.
21. **Liu CD**, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal peptide YY induces colonic absorption in vivo. *Dis Colon Rectum*, **39**:A22, 1996.
22. **Liu CD**, Simon N, McFadden DW. Synthetic biotinylated peptide YY(22-36) binds to human pancreatic cancer cells. *Journal of Surgical Research*, **86**:293,1999.
23. **Liu CD**, Saxton RE, McFadden DW. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. *Journal of Surgical Research*, **86**:260, 1999.
24. Patel KR, Rose AT, **Liu CD**, McFadden DW. Human pancreatic cancer growth is inhibited by peptide Y Y4 receptor specific analog BA-129. *Gastroenterology*, **118**: 4 Suppl, A538, 2000.
25. **Liu CD**, Case M, McFadden DW, Kwan D, Paiva M. Saxton RE. Neutral red-doped albumin as a new sealant for intestinal laser soldering. *Gastroenterology*, **118**:4 Suppl. A1048, 2000.
26. **Liu CD**, Kwan D, Simon N, McFadden DW. Synthetic PYY analog binds to a 68 kD cell membrane receptor and delivers fluorescent dye for imaging and therapeutic treatment of human pancreatic cancers. *Gastroenterology*, **118**:4 Suppl, A1054, 2000.
27. **Liu CD**, Tilch L, Simon N, McFadden DW. Increased levels of vascular endothelial growth factor (VEGF) in ascites from metastatic pancreatic cancer. *Gastroenterology*, **118**: 4 Suppl, A1398, 2000.
28. **Liu CD**, Yaghoubian AT, Kwan D, McFadden DW, Paiva M, Saxton RE. Photodynamic therapy by two dye cascade of human pancreatic cancer suppresses vascular endothelial growth factor and cell growth. *Gastroenterology*, April 2001 (Vol. 120, Issue 5, Page A-350)
29. **Liu CD**, Kwan D. The combined endo-GIA linear stapled and hand-sewn bowel anastomosis is more efficient and safer for laparoscopic Roux en Y gastric bypass. *Gastroenterology*, April 2001 (Vol. 120, Issue 5, pages A-490)
30. **Liu CD**, Alexander P, Arthur, D. Cost-analysis of laparoscopic versus open Roux-en-Y gastric bypass for morbid obesity. *Obesity Surgery*, **11**(2):165, 2001.
31. Deganutti A, **Liu CD**. Synthetic peptide YY analog is pH dependent during pancreatic cancer cell growth inhibition. *Journal of Surgical Research*, **100**(2):277-8, 2001.

32. Puopong DP, **Liu CD**. Cost effectiveness of gastric bypass Roux en Y for adult onset diabetes *Journal of Surgical Research*, **100**(2):263-4, 2001.
33. Huerta S, Ko C, **Liu CD**, Livingston EH. Sensitivity analysis for 10 predictive risk factors for bariatric surgery complications. *Journal of Surgical Research*, **100**(2):247, 2001.
34. Deganutti A, Saxton RE, **Liu CD**. Gene expression changes and growth inhibition of human pancreatic cancer with COX-2 enzyme inhibition. *Journal of Surgical Research*, **100**(2):300-1, 2001.
35. Tseng WW, Chen MN, Deganutti A, Saxton RE, **Liu CD**. Selective cyclooxygenase-2 inhibitor rofecoxib, Vioxx, induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. *Gastroenterology*, 2002.
36. Tseng WW, Saxton RE, **Liu CD**. Laser activation of indocyanine green induces dose-dependent cytotoxicity in multiple human pancreatic cancer cell lines *Gastroenterology*, 2002.
37. **Liu CD**, Glantz GJ, Livingston EH. Fibrin glue as a sealant for high-risk anastomosis for morbid obesity surgery. *Obesity Surgery*, 2002.
38. **Liu CD**, Glantz GJ, Livingston EH. Management of post-operative leaks in Roux-en-Y gastric bypass patients: argument for selective radiologic studies. *Obesity Surgery*, 2002.
39. Deganutti A, **Liu CD**. Apoptotic pathway is induced with SSPYY by activation of 68kD cell membrane receptor with an increase in cytoplasmic ERK-1 and an increase in nuclear Elk-1 transcription factor to induce pancreatic cancer cell death. *Gastroenterology*, 2003. April 2003 (Vol. 124, Issue 4, Page A803)
40. **Liu CD**, Kim C. Resolution of diabetes after Roux en Y gastric bypass. *Gastroenterology*, 2004.
41. **Liu CD**, Kim CY. Resolution of hypersensitivity disorders after weight loss surgery. *Obesity Surgery*, 2004.
42. Sebastian J, **Liu CD**. The use of albumin impregnated mesh for port placement during LAP-BAND insertion. *Obesity Surgery*, 2004.
43. **Liu CD**. Weight Loss Surgery in Ambulatory Surgery Centers. *Gastroenterology*, 2007.
44. **Liu CD**. The use of self-tying nitinol sutures in laparoscopic adjustable gastric banding. *Gastroenterology*, 2007.
45. **Liu CD**. Early regression of metabolic syndrome and diabetes in laparoscopic adjustable gastric banding vs. gastric bypass. *Gastroenterology*, 2007.

46. Dacuycuy L, **Liu CD**. Use of Polypropylene Mesh for Laparoscopic Adjustable Gastric Banding (LAGB) Allows for Minimum Post-Op Pain with No Narcotic Usage and Less Pain for Adjustments. Submitted for Presentation at annual meeting of the American Society for Metabolic and Bariatric Surgery Meeting. 2008. *Gastroenterology* April, 2008 (Vol. 134, Issue 4, Pages A-891)
47. **Liu CD**, Dacuycuy L. Resolution of Gastroesophageal Reflux With Laparoscopic Adjustable Gastric Banding. *Gastroenterology*, May 2009 (Vol. 136, Issue 5, Pages A-914)
48. **Liu CD**, Simpson T, Bhojrul S. Multi-Center Report of the Use of Polypropylene Mesh for Laparoscopic Adjustable Gastric Banding (LAGB) Allows for Minimum Post-Op Pain, Less Use of Narcotics, and Less Pain During Adjustments *Gastroenterology*, May 2009 (Vol. 136, Issue 5, Pages A-920)
49. Nguyen DA, Schwarzman A, **Liu CD**. Laparoscopic Adjustable Gastric Banding (LAGB) in super morbidly obese patients (BMI>50) in Ambulatory Surgery Center is Safe. *Journal of Gastrointestinal Surgery*, May 2010.
50. Nguyen DA, Schwarzman A, **Liu CD**. Successful Weight Loss with Laparoscopic Adjustable Gastric Banding is Achieved with More Frequent Adjustments than Visits. *Surgery for Obesity and Related Diseases*, June 2010.
51. Nguyen DA, Schwarzman A, **Liu CD**. Change in Body Mass Index is a Better Predictor of Resolution of Comorbidities Than Percentage Excess Weight Loss in Laparoscopic Adjustable Gastric Banding. *Journal of the Society of Laparoendoscopic Surgeons*, September 2010.
52. Nguyen DA, Kim GJ, **Liu CD**. Diabetic Patients Have Less Lean Body Mass which is Correlated with Less Excess Weight Loss in Laparoscopic Adjustable Gastric Banding (LAGB) Over Three Years, N=601. *Journal of Gastrointestinal Surgery*, May 2011.
53. Nguyen DA, Kim GJ, **Liu CD**. Is there a Golden Window for the LAP-BANDTM: Greater Intra-Band Pressure is Needed as Time Passes with LAGB? *Journal of Gastrointestinal Surgery*, May 2011.
54. Nguyen DA, Kim GJ, **Liu CD**. Successful Weight Loss with Laparoscopic Adjustable Gastric Banding (LAGB) is Directly Dependent on the Number of Adjustments in the First Three Years, N=601. *Surgery for Obesity and Related Diseases*, June 2011.
55. Nguyen DA, Kim GJ, **Liu CD**. Variability of Outcome after Laparoscopic Adjustable Gastric Banding (LAGB) in Obese Patients is Correlated with Financial Status. *Surgery for Obesity and Related Diseases*, June 2011.
56. Nguyen DA, Kim GJ, **Liu CD**. Gender Differences in Weight Loss are Diminished Three years Post-Operative Band Implantation in Laparoscopic Adjustable Gastric Banding (LAGB) Patients, N=601. *Surgery for Obesity and Related Diseases*, June 2011.

57. Nguyen DA, Kim GJ, **Liu CD**. Is Weight Loss Correlated with Race in Laparoscopic Adjustable Gastric Banding (LAGB) Patients? Yes. Pending for *Journal of the Society of Laparoendoscopic Surgeons*, September 2011.

Presentations

1. **Liu CD**, Aloia T, Hines OJ, Ashley SW, Newton T, Whang E, Zinner MJ, Bilchik AJ, McFadden DW. Peptide YY Is A Proabsorptive Agent In The Canine Colon In Vivo. Presented at the American Gastroenterological Association Fall Symposium, Chicago, 1993.
2. Whang E, Hines OJ, **Liu CD**, Moser J, Zinner MJ, McFadden DW, Ashley SW. Peptide YY Does Not Modulate Jejunal Glucose Absorption In Vitro. Presented at the American Gastroenterological Association Fall Symposium, Chicago, 1993.
3. **Liu CD**, Aloia T, Hines OJ, Ashley SW, Newton T, Whang EE, Zinner MJ, Bilchik AJ, McFadden DW. PYY: A Proabsorptive Agent In The Canine Colon In Vivo. Presented at the annual meeting of the Center of Ulcer Research and Education, Los Angeles, CA, 1994.
4. Whang EE, Hines OJ, **Liu CD**, Moser AJ, Zinner MJ, McFadden DW, Ashley SW. Peptide YY Does Not Modulate Jejunal Glucose Transport In Vitro. Presented at the annual meeting of the Center of Ulcer Research and Education, Los Angeles, CA, 1994.
5. Bilchik AJ, Hines OJ, Ashley SW, Adrian TE, **Liu CD**, Wong H, Zinner MJ, McFadden DW. Peptide YY Immunoneutralization Inhibits Meal-Induced Absorption In Vivo. Presented at the annual meeting of the Center of Ulcer Research and Education, Los Angeles, CA, 1994.
6. **Liu CD**, Hines OJ, Whang EE, Laird EC, Skotzko MJ, Zinner MJ, Ashley SW, McFadden DW. Pancreatic Peptide YY mRNA Levels Increase During Adaptation After Small Intestinal Resection. Presented at the Plenary Session of the annual meeting of the Association of VA Surgeons, Reno, NV, 1994.
7. Hines OJ, Bilchik AJ, Ashley SW, Whang EE, **Liu CD**, Zinner MJ, McFadden DW. Amino Acids Mediate Postprandial Jejunal Proabsorption. Presented at the Plenary Session of the annual meeting of the Association of VA Surgeons, Reno, NV, 1994.
8. Bilchik AJ, Hines OJ, Ashley SW, Adrian TE, **Liu CD**, Wong H, Zinner MJ, McFadden DW. Peptide YY Immunoneutralization Inhibits Meal-Induced Absorption In Vivo. Presented at the annual meeting of the American Association of Endocrine Surgeons, Detroit, MI, 1994.
9. **Liu CD**, Hines OJ, Whang EE, Bilchik AJ, Ashley SW, Zinner MJ, Newton TR, McFadden DW. Cholecystokinin (CCK) Mediates Colonic Absorption Via Peptide YY

- (PYY). Presented at the annual meeting of the Society for Surgeons of the Alimentary Tract and Ross Laboratories, New Orleans, LA, 1994.
10. Whang EE, Hines OJ, **Liu CD**, Reeves JR, Moser AJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. Both Y1-Specific And Y2-sPecific Peptide YY Agonists Modulate Colonic Ion Transport. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, LA, 1994.
 11. **Liu CD**, Balasubramaniam A, Hines OJ, Whang EE, Newton TR, Zinner MJ, Ashley SW, McFadden DW. A New Synthetic Analogue Of Peptide YY, BIM-4004-1, Is Proabsorptive In The Small Intestine Of Awake Dogs. Presented at the Plenary Session of the 10th Intemational Symposium on Gastrointestinal Hormones, Santa Barbara, CA, 1994.
 12. **Liu CD**, Aloia T, Hines OJ, Adrian TE, Whang EE, Zinner MJ, Ashley SW, McFadden DW. Cholecystokinin Receptor Blockade Down Regulates Na⁺/K⁺ Cotransporter mRNA After Intestinal Resection. Presented at the 10th Intemational Symposium on Gastrointestinal Hormones, Santa Barbara, CA, 1994.
 13. Whang EE, Hines OJ, **Liu CD**, Reeve JR, Moser AJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. The Role Of Peptide YY Receptor Subtypes In Colonic Ion Transport Regulation. Presented at the 10th Intemational Symposium on Gastrointestinal Hormones, Santa Barbara, CA, 1994.
 14. **Liu CD**, Hines OJ, Whang EE, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Cholecystokinin Mediates Colonic Absorption. Presented as a Grassi prize finalist at the annual meeting of the Collegium Internationale Chirurgiae Digestivae, Los Angeles, CA, 1994.
 15. Whang EE, Hines OJ, **Liu CD**, Reeve JR, Moser AJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. Both Y1- Specific And Y2-Specific Peptide YY Receptor Agonists Modulate Colonic Ion Transport. Presented at the annual meeting of the Collegium Intemationale Chirurgiae Digestivae, 14th World Congress, Los Angeles, CA, 1994.
 16. **Liu CD**, Whang EE, Hines OJ, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal Peptide YY Is Proabsorptive In The Canine Ileum In Vivo. Presented at the annual meeting of the American College of Surgeons, Surgical Forum, Chicago, IL, 1994.
 17. Whang EE, Hines OJ, **Liu CD**, Reeve JR, Bilchik AJ, Moser AJ, Zinner MJ, McFadden DW, Ashley SW. Mechanisms Of Peptide YY - Induced Colonic Absorption. Presented at the annual meeting of the American College of Surgeons, Surgical Forum, Chicago, IL, 1994.
 18. **Liu CD**, Slice L, Balasubrumian A, Walsh JH, Newton TR, Saxton RE, McFadden DW. A Novel Synthetic Peptide Decreases Human Pancreatic Cancer Growth And Intracellular cAMP Levels. Presented at the annual meeting of the Los Angeles Surgical Society, Los Angeles, CA, 1994.

19. **Liu CD**, Balasubramaniam A, Saxton RE, Paiva M, McFadden DW. Human Pancreatic Cancer Growth Is Inhibited By Peptide YY And Its Synthetic Analog, BIM-43004-1. Presented at the annual meeting of the Association of Academic Surgeons, Albuquerque, NM, 1994.
20. **Liu CD**, Hines OJ, Whang EE , Balasubramaniam A, Newton TR, Zinner MJ, Ashley SW, McFadden DW. A New Synthetic Analog Of Peptide YY Given Intraluminally Induces Intestinal Absorption. Presented at the annual meeting of the Association of Academic Surgeons, Albuquerque, NM, 1994.
21. **Liu CD**, Ashley SW, Rolandelli R, Evans B, Shin M, McFadden DW. Laparoscopic Intestinal Surgery In Inflammatory Bowel Disease Patients. Presented at the annual meeting of the Southern California Chapter of the American College of Surgeons, Indian Wells, CA, 1995.
22. **Liu CD**, Aloia T, Hines OJ, Bilchik AJ, Whang EE, MD, Newton TR, Zinner MJ, Ashley SW, and McFadden DW. Peptide YY : A Potential Proabsorptive Enteric Hormone In The Treatment Of Colonic Malabsorptive Disorders. Presented at the annual meeting of the Southern California Chapter of the American College of Surgeons, Indian Wells, CA, 1995.
23. **Liu CD**, Slice L, Balasubrumian A, Walsh JH, Newton TR, Saxton RE, McFadden DW. Y2 Receptors Decrease Human Pancreatic Cancer Growth And Intracellular cAMP Levels. Presented at the Plenary Session of the annual meeting of the Society of University Surgeons, Denver, CO, 1995.
24. Whang EE, Hines OJ, **Liu CD**, Reeve JR, Grandt D, Bilchik AJ, Moser JA, Zinner MJ, McFadden DW, Ashley SW. Mechanisms of Peptide YY-Induced Colonic Absorption. Presented at the annual meeting of the Center of Ulcer Research and Education, Los Angeles, CA, 1995.
25. **Liu CD**, Rongione AJ, Adrian TE, Laird EC, Shin M, Ashley SW, McFadden DW. Cholecystokinin Regulates Na⁺/K⁺ ATPase mRNA After Intestinal Resection. Presented at the annual meeting of the Center of Ulcer Research and Education, Los Angeles, CA, 1995.
26. **Liu CD**, Rongione AJ, Balasubramaniam A, Ashley SW, McFadden DW. Pancreatic Cancer Growth and Transforming Growth Factor-Alpha Are Decreased When Exposed to Synthetic Peptide YY Analog. Presented at the Plenary Session of the 19th Annual Association of VA Surgeons Meeting, Pittsburgh, PA, 1995.
27. Dunn JC, Whang EE, **Liu CD**, Newton T, Zinner MJ, McFadden DW, Ashley SW. Amiloride Inhibits Meal-Induced Colonic Absorption. Presented at the Plenary Session of the 19th Annual Association of VA Surgeons Meeting, Pittsburgh, PA, 1995.
28. Rongione AJ, **Liu CD**, Whang EE, Dunn JC, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Inhibitory Effects of Galanin Upon Meal-Induced Absorption in the

- Awake Canine Model. Presented at the 19th Annual Association of VA Surgeons Meeting, Pittsburgh, PA, 1995.
29. **Liu CD**, Rongione A, Garvey L, McFadden DW. Adjuvant Hormonal Treatment With Peptide YY And Its Analog Decreases Human Pancreatic Carcinoma Growth and EGF Receptors. Presented at the annual meeting of the Society for Surgery of the Alimentary Tract, San Diego, CA, 1995.
 30. **Liu CD**, Rongione AJ, Shin M, Kwan KY, Ashley SW, McFadden DW. Intestinal Adaptation Is Regulated By Systemic Factors Independent Of Intraluminal Contents. Presented at annual meeting of the American Gastroenterological Association, San Diego, CA, 1995.
 31. Rongione AJ, **Liu CD**, Bilchik AJ, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal Bile Salts Regulate Small Bowel Absorption. Presented at annual meeting of the American Gastroenterological Association, San Diego, CA, 1995.
 32. **Liu CD**, Rongione AJ, Balasubramaniam A, Newton TR, McFadden DW. Synthetic Peptide YY Analog In The Treatment Of Human Pancreatic Cancer. Presented at the plenary session of the Pancreas Club, San Diego, CA, 1995.
 33. **Liu CD**, Rongione AJ, Shin M, Ashley SW, McFadden DW. Epidermal Growth Factor Improves Intestinal Adaptation During Somatostatin Administration. Presented at the Annual Meeting of the Association for Academic Surgery, Detroit, MI, 1995.
 34. **Liu CD**, Rongione AJ, Balasubramaniam A, Slice L, McFadden DW. Characterization of A Novel Receptor Associated With Decreased Human Pancreatic Cancer Growth. Presented at the Annual Meeting of the Society of Surgical Oncology, Atlanta, GA, 1996.
 35. **Liu CD**, Newton TR, Zinner MJ, Ashley SW, McFadden DW. Intraluminal Peptide YY Induces Colonic Absorption in Vivo. Presented at the Annual Meeting of the American Society of Colon and Rectal Surgeons, Seattle, WA, 1996.
 36. **Liu CD**, McFadden DW. Overnight Closed Suction Drainage After Lumpectomy and Axillary Lymphadenectomy for Breast Cancer. Presented at the Annual Meeting of the Southern California American College of Surgeons Meeting, Dana Point, CA, 1997.
 37. **Liu CD**. Pancreatic Neuroendocrine Tumors. Presented at the Annual Meeting of the Southern California American College of Surgeons Meeting, Santa Barbara, CA, 1999.
 38. Heisler T, Towfigh S, Simon N, **Liu C**, McFadden DW. Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth. Presented at the Annual Meeting of the Association of VA Surgeons, St. Louis, MO, 1999.
 39. **Liu CD**, Simon N, McFadden DW. Synthetic Biotinylated Peptide YY(22-36) Binds to Human Pancreatic Cancer Cells. Presented at the Annual Meeting of the Association for Academic Surgery, Philadelphia, PA, 1999.

40. **Liu CD**, Saxton RE, McFadden DW. Hypericin and Photodynamic Therapy Decreases Human Pancreatic Cancer In Vitro and In Vivo. Presented at the Annual Meeting of the Association for Academic Surgery, Philadelphia, PA, 1999.
41. **Liu CD**, McFadden DW. Laparoscopic Port Sites Do Not Require Fascial Closure When Using Non-Bladed Trocars. Presented at the Annual Meeting of the Southern California American College of Surgeons Meeting, Huntington Beach, CA, 2000.
42. **Liu CD**, Kwan D, Yaghoubian A, Saxton RE, McFadden DW. Hypericin and Neutral Red Photodynamic Therapy Decreases Pancreatic Cancer Cell Growth and Vascular Endothelial Growth Factor. Presented at the Annual Meeting of the Association of VA Surgeons, Seattle, WA, 2000.
43. **Liu CD**, Kwan D, Simon N, McFadden DW. Synthetic Peptide YY Analog Binds to a 68 kD Cell Membrane Receptor and Delivers Fluorescent Dye for Imaging and Therapeutic Treatment of Human Pancreatic Cancers. Presented at the Plenary Session of the Society for Surgery of the Alimentary Tract, San Diego, May 2000.
44. **Liu CD**, Case M, McFadden DW, Kwan D, Paiva M, Saxton RE. Neutral Red-Doped Albumin as a New Sealant for Intestinal Laser Soldering. Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, San Diego, May 2000.
45. Tseng WW, Saxton RE, Kwan DW, **Liu CD**. Indocyanine green decreases cell viability and impairs production of vascular endothelial growth factor in pancreatic cancer. Presented at the Annual Meeting of the Society for Surgical Oncology, Washington D.C., March 2001.
46. **Liu CD**. Photodynamic therapy of pancreatic cancer. Presented at the Veterans Administration Alumni Association Conference, Los Angeles, March 2001.
47. **Liu CD**. Synthetic gut hormones in the treatment of pancreatic cancer. Presented at the California Cancer Research Program Symposium, Sacramento, May 2001.
48. **Liu CD**. "What's new in minimally invasive bariatric surgery" Presented at the Los Angeles Surgical Society, May 2001.
49. **Liu CD**, Tilch L, Kwan D, McFadden DW. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. Presented at the Plenary Session of the Annual Meeting of Association of VA Surgeons, Atlanta May 2001.
50. **Liu CD**, Yaghoubian AT, Kwan D, McFadden DW, Paiva M, Saxton RE. Photodynamic therapy by two dye cascade of human pancreatic cancer suppresses vascular endothelial growth factor and cell growth. Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, Atlanta, May 2001.
51. **Liu CD**, Kwan D. The combined endo-GIA linear stapled and hand-sewn bowel anastomosis is more efficient and safer for laparoscopic Roux en Y gastric bypass.

Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, Atlanta, May 2001.

52. **Liu CD**, Alexander P, Arthur D. Cost Analysis of Laparoscopic versus Open Roux en Y Gastric Bypass for Morbid Obesity. Presented at the Annual Meeting of the American Society for Bariatric Surgery, Washington D.C., June 2001.
53. **Liu CD**. Fibrin Sealant in Surgery. Washington D.C., June 2001.
54. **Liu CD**, Higa K, Guenther M, et al. Roundtable Discussion of Fibrin Sealants in Surgery. Chairman of Conference. Pheonix, August, 2001.
55. **Liu CD**, Deganutti A, Saxton RE. Cyclooxygenase-2 (COX-2) inhibition decreases human pancreatic cancer cell growth and angiogenesis. Presented at the Annual Clinical Congress of the American College of Surgeons, New Orleans, October 2001.
56. Chen M, Kwan D, Saxton RE, **Liu CD**. Hypericin photodynamic therapy decreases melanoma cell growth in vitro. Presented at the Annual Clinical Congress of the American College of Surgeons, New Orleans, October 2001.
57. Deganutti A, **Liu CD**. Synthetic peptide YY analog is pH dependent during pancreatic cancer cell growth inhibition. Presented at the Annual Meeting of the Association for Academic Surgery, Milwaukee, November 2001.
58. Puopong DP, **Liu CD**. Cost effectiveness of gastric bypass Roux en Y for adult onset diabetes. Presented at the Annual Meeting of the Association for Academic Surgery, Milwaukee, November 2001.
59. Deganutti A, Saxton RE, **Liu CD**. Gene expression changes and growth inhibition of human pancreatic cancer with COX-2 enzyme inhibition. Presented at the Annual Meeting of the Association for Academic Surgery, Milwaukee, November 2001.
60. Huerta S, Ko C, **Liu CD**, Livingston EH. Sensitivity analysis for 10 predictive risk factors for bariatric surgery complications. Presented at the Annual Meeting of the Association for Academic Surgery, Milwaukee, November 2001.
61. **Liu CD**, Tseng W. Robotic-assisted and robotic laparoscopic gastric bypass Roux en Y. Presented at the Annual Meeting of the Southern California American College of Surgeons Meeting, Santa Barbara, January 2002.
62. **Liu CD**. From Minimally to Molecularly Invasive Surgery. University of California Los Angeles Grand Rounds, Los Angeles, February 2002.
63. Tseng WW, Chen MN, Deganutti A, Saxton RE, **Liu CD**. Selective cyclooxygenase-2 inhibitor rofecoxib, Vioxx, induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. Presented at the Presidential Plenary Session at the Annual Meeting of the Society for Surgery of the Alimentary Tract, San Francisco, May 2002.

64. Tseng WW, Saxton RE, **Liu CD**. Laser activation of indocyanine green induces dose-dependent cytotoxicity in multiple human pancreatic cancer cell lines. Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, San Francisco, May 2002.
65. **Liu CD**, Glantz GJ, Livingston EH. Fibrin glue as a sealant for high-risk anastomosis for morbid obesity surgery. Presented in the Plenary Session at the Annual Meeting of the American Society for Bariatric Surgery, Las Vegas, June 2002.
66. **Liu CD**, Glantz GJ, Livingston EH. Management of post-operative leaks in Roux-en-Y gastric bypass patients: argument for selective radiologic studies. Presented at the Annual Meeting of the American Society for Bariatric Surgery, Las Vegas, June 2002.
67. Deganutti A, **Liu CD**. Apoptotic pathway is induced with SSPYY by activation of 68kD cell membrane receptor with an increase in cytoplasmic ERK-1 and an increase in nuclear Elk-1 transcription factor to induce pancreatic cancer cell death. Presented at the annual Society for Surgery of the Alimentary Tract, Orlando, May 2003.
68. **Liu CD**. Weight Loss Surgery Options: Community Outreach Lecture, Bakersfield, CA, April 9, 2003.
69. **Liu CD**. Local Physician Education Lecture, Beverly Hills, CA, April 23, 2003.
70. **Liu CD**. Laparoscopic Weight Loss Surgery: Community Outreach Lecture, Woodland Hills, CA, April 30, 2003.
71. **Liu CD**. Laparoscopic versus Open Weight Loss Surgery. Community Outreach Lecture, Santa Clarita, CA, May 21, 2003.
72. **Liu CD**. Laparoscopic Gastric Bypass Surgery At Century City: Community Outreach Lecture, Los Angeles, CA, May 17, 2003.
73. **Liu CD**. Nationwide Live Webcast: Fibrin Sealants in Bariatric Surgery, Los Angeles, CA, August 13, 2003.
74. **Liu CD**. Laparoscopic Ventral Hernia Repairs. Invited Lecturer, Camarillo, CA, August 19, 2003.
75. **Liu CD**. Laparoscopic Ventral Hernia Repairs-The Next Frontier. Grand Rounds Speaker, Cottage Hospital, Santa Barbara, CA, August 20, 2003.
76. **Liu CD**. Laparoscopic Gastric Bypass vs. LAP-BAND. Community Lecture, Torrance, CA, August 26, 2003.
77. **Liu CD**. Laparoscopic Weight Loss Procedures. Lecture, Long Beach, CA September 17, 2003.

78. **Liu CD.** Bariatric Surgery: Indications for Weight Loss Surgery. Grand Rounds Speaker, Methodist Hospital, Dallas, TX, November 21, 2003.
79. **Liu CD, Kim C.** Resolution of diabetes after Roux en Y gastric bypass. Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, New Orleans, LA, May 2004.
80. **Liu CD, Kim CY.** Resolution of hypersensitivity disorders after weight loss surgery. Presented at the annual meeting of the American Society for Bariatric Surgery, San Diego, CA, June 2004.
81. Sebastian J, **Liu CD.** The use of albumin impregnated mesh for port placement during LAP-BAND insertion,. Presented at the annual meeting of the American Society for Bariatric Surgery, San Diego, CA, June 2004.
82. Agopian V, **Liu C, Stelzner M, Sebastian J.** Laparoscopic adjustable gastric banding in the veteran population: A single institution's early experience. Presented at the annual meeting of the Association of VA Surgeon's Meeting 2005.
83. Sultana Y, Don Michael TA, **Liu CD.** Early regression of metabolic syndrome and diabetes following weight loss surgery. Presented at the annual meeting of the Southern California American College of Surgeons Meeting, Santa Barbara, CA 2007.
84. **Liu CD.** Weight Loss Surgery in Ambulatory Surgery Centers. Presented at the annual meeting of the Society for Surgery of the Alimentary Tract, Washington D.C., May 2007.
85. **Liu CD.** Role of Bariatric Surgery: Outpatient Weight Loss Surgery. Presented at the Aesthetic Show, Las Vegas, NV, May 2007.
86. **Liu CD.** Latest Advances in Bariatric Surgery. Presented at the annual VA Alumni Awards Meeting, Los Angeles, CA, March 2008.
87. Dacuycuy L, **Liu CD.** Use of Polypropylene Mesh for Laparoscopic Adjustable Gastric Banding (LAGB) Allows for Minimum Post-Op Pain with No Narcotic Usage and Less Pain for Adjustments. Presented at annual meeting of the American Society for Metabolic and Bariatric Surgery Meeting. Grapevine, TX, April 2008.
88. **Liu CD, Dacuycuy L.** Resolution of Gastroesophageal Reflux With Laparoscopic Adjustable Gastric Banding. Presented at Annual Meeting of Society for Surgery of the Alimentary Tract, Chicago, IL, May 2009.
89. Horwith A, Osborne D, **Liu CD.** Nitinol Is a Superior Suture Material for Funduplications in Laparoscopic Adjustable Gastric Banding Procedures. Presented at Annual Meeting of Society for Surgery of the Alimentary Tract, Chicago, IL May 2009.

90. **Liu CD**, Simpson T, Bhojru S. Multi-Center Report of the Use of Polypropylene Mesh for Laparoscopic Adjustable Gastric Banding (LAGB) Allows for Minimum Post-Op Pain, Less Use of Narcotics, and Less Pain During Adjustments, Chicago, IL, May 2009.
91. Nguyen DA, Schwarzman A, **Liu CD**. Laparoscopic Adjustable Gastric Banding (LAGB) in super morbidly obese patients (BMI>50) in Ambulatory Surgery Center is Safe. Presented at the Annual Meeting of Society for Surgery of the Alimentary Tract, New Orleans, LA, May 2010.
92. Nguyen DA, Schwarzman A, **Liu CD**. Successful Weight Loss with Laparoscopic Adjustable Gastric Banding is Achieved with More Frequent Adjustments than Visits. Presented at the Annual Meeting of American Society for Metabolic and Bariatric Surgery (ASMBS), Las Vegas, NV, June 2010.
93. Nguyen DA, Schwarzman A, **Liu CD**. Change in Body Mass Index is a Better Predictor of Resolution of Comorbidities Than Percentage Excess Weight Loss in Laparoscopic Adjustable Gastric Banding. Presented at the Annual Meeting of Society of Laparoendoscopic Surgeons, New York, NY, August 2010.
94. Nguyen DA, Kim GJ, **Liu CD**. Diabetic Patients Have Less Lean Body Mass which is Correlated with Less Excess Weight Loss in Laparoscopic Adjustable Gastric Banding (LAGB) Over Three Years, N=601. Presented at the Annual Meeting of Society for Surgery of the Alimentary Tract, Chicago, IL, May 2011.
95. Nguyen DA, Kim GJ, **Liu CD**. Is there a Golden Window for the LAP-BAND™: Greater Intra-Band Pressure is Needed as Time Passes with LAGB? Presented at the Annual Meeting of Society for Surgery of the Alimentary Tract, Chicago, IL, May 2011.
96. Nguyen DA, Kim GJ, **Liu CD**. Successful Weight Loss with Laparoscopic Adjustable Gastric Banding (LAGB) is Directly Dependent on the Number of Adjustments in the First Three Years, N=601. Presented at the Annual Meeting of American Society for Metabolic and Bariatric Surgery (ASMBS), Orlando, FL, June 2011.
97. Nguyen DA, Kim GJ, **Liu CD**. Variability of Outcome after Laparoscopic Adjustable Gastric Banding (LAGB) in Obese Patients is Correlated with Financial Status. Presented at the Annual Meeting of American Society for Metabolic and Bariatric Surgery (ASMBS), Orlando, FL, June 2011.
98. Nguyen DA, Kim GJ, **Liu CD**. Gender Differences in Weight Loss are Diminished Three years Post-Operative Band Implantation in Laparoscopic Adjustable Gastric Banding (LAGB) Patients, N=601. Presented at the Annual Meeting of American Society for Metabolic and Bariatric Surgery (ASMBS), Orlando, FL, June 2011.
99. Nguyen DA, Kim GJ, **Liu CD**. Is Weight Loss Correlated with Race in Laparoscopic Adjustable Gastric Banding (LAGB) Patients? Yes. Pending for presentation at the Annual Meeting of Society of Laparoendoscopic Surgeons, Los Angeles, CA, September 2011.